nodes	percent_of_prediction	percent_of_DWPC	metapath
Etravirine—CYP2C9—Estropipate—osteoporosis	0.0843	0.129	CbGbCtD
Etravirine—ABCB1—Ethinyl Estradiol—osteoporosis	0.0527	0.0808	CbGbCtD
Etravirine—CYP2C19—Cholecalciferol—osteoporosis	0.0522	0.08	CbGbCtD
Etravirine—CYP3A4—Estropipate—osteoporosis	0.049	0.0751	CbGbCtD
Etravirine—CYP3A4—Calcitriol—osteoporosis	0.049	0.0751	CbGbCtD
Etravirine—CYP2C9—Cholecalciferol—osteoporosis	0.0434	0.0665	CbGbCtD
Etravirine—CYP2C19—Estradiol—osteoporosis	0.0421	0.0645	CbGbCtD
Etravirine—CYP3A4—Ergocalciferol—osteoporosis	0.0392	0.06	CbGbCtD
Etravirine—ABCB1—Conjugated Estrogens—osteoporosis	0.0387	0.0593	CbGbCtD
Etravirine—CYP2C9—Estradiol—osteoporosis	0.035	0.0536	CbGbCtD
Etravirine—ABCB1—Estradiol—osteoporosis	0.034	0.052	CbGbCtD
Etravirine—CYP3A4—Raloxifene—osteoporosis	0.0327	0.0501	CbGbCtD
Etravirine—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0316	0.0484	CbGbCtD
Etravirine—CYP3A4—Cholecalciferol—osteoporosis	0.0253	0.0387	CbGbCtD
Etravirine—CYP3A4—Conjugated Estrogens—osteoporosis	0.0232	0.0355	CbGbCtD
Etravirine—CYP3A4—Estradiol—osteoporosis	0.0204	0.0312	CbGbCtD
Etravirine—ABCB1—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.00212	0.0809	CbGpPWpGaD
Etravirine—ABCB4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	0.00197	0.0751	CbGpPWpGaD
Etravirine—ABCB4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.00151	0.0577	CbGpPWpGaD
Etravirine—ABCB4—Fatty acid, triacylglycerol, and ketone body metabolism—GPD2—osteoporosis	0.00143	0.0546	CbGpPWpGaD
Etravirine—CYP3A4—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.00131	0.0498	CbGpPWpGaD
Etravirine—ABCB4—Fatty acid, triacylglycerol, and ketone body metabolism—OXCT1—osteoporosis	0.00111	0.0425	CbGpPWpGaD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000602	0.023	CbGpPWpGaD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.00057	0.0218	CbGpPWpGaD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000444	0.0169	CbGpPWpGaD
Etravirine—ABCB1—HIF-1-alpha transcription factor network—PKM—osteoporosis	0.000434	0.0165	CbGpPWpGaD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000432	0.0165	CbGpPWpGaD
Etravirine—Shock—Risedronate—osteoporosis	0.000363	0.00113	CcSEcCtD
Etravirine—Anaemia—Zoledronate—osteoporosis	0.000363	0.00113	CcSEcCtD
Etravirine—Nervous system disorder—Risedronate—osteoporosis	0.000362	0.00113	CcSEcCtD
Etravirine—Discomfort—Pamidronate—osteoporosis	0.000361	0.00113	CcSEcCtD
Etravirine—Angioedema—Zoledronate—osteoporosis	0.000358	0.00112	CcSEcCtD
Etravirine—Skin disorder—Risedronate—osteoporosis	0.000358	0.00112	CcSEcCtD
Etravirine—Gastrointestinal pain—Calcitriol—osteoporosis	0.000358	0.00112	CcSEcCtD
Etravirine—Abdominal pain—Raloxifene—osteoporosis	0.000357	0.00111	CcSEcCtD
Etravirine—Body temperature increased—Raloxifene—osteoporosis	0.000357	0.00111	CcSEcCtD
Etravirine—Vision blurred—Conjugated Estrogens—osteoporosis	0.000356	0.00111	CcSEcCtD
Etravirine—Malaise—Zoledronate—osteoporosis	0.000354	0.0011	CcSEcCtD
Etravirine—Body temperature increased—Ibandronate—osteoporosis	0.000354	0.0011	CcSEcCtD
Etravirine—Abdominal pain—Ibandronate—osteoporosis	0.000354	0.0011	CcSEcCtD
Etravirine—Confusional state—Pamidronate—osteoporosis	0.000353	0.0011	CcSEcCtD
Etravirine—Vertigo—Zoledronate—osteoporosis	0.000352	0.0011	CcSEcCtD
Etravirine—Syncope—Zoledronate—osteoporosis	0.000352	0.0011	CcSEcCtD
Etravirine—Infection—Pamidronate—osteoporosis	0.000348	0.00109	CcSEcCtD
Etravirine—Hepatitis—Estradiol—osteoporosis	0.000347	0.00108	CcSEcCtD
Etravirine—Body temperature increased—Calcitriol—osteoporosis	0.000346	0.00108	CcSEcCtD
Etravirine—Abdominal pain—Calcitriol—osteoporosis	0.000346	0.00108	CcSEcCtD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000346	0.0132	CbGpPWpGaD
Etravirine—Hypoaesthesia—Estradiol—osteoporosis	0.000346	0.00108	CcSEcCtD
Etravirine—Angioedema—Conjugated Estrogens—osteoporosis	0.000345	0.00108	CcSEcCtD
Etravirine—Shock—Pamidronate—osteoporosis	0.000345	0.00107	CcSEcCtD
Etravirine—Loss of consciousness—Zoledronate—osteoporosis	0.000345	0.00107	CcSEcCtD
Etravirine—Hypersensitivity—Estropipate—osteoporosis	0.000344	0.00107	CcSEcCtD
Etravirine—Nervous system disorder—Pamidronate—osteoporosis	0.000344	0.00107	CcSEcCtD
Etravirine—Thrombocytopenia—Pamidronate—osteoporosis	0.000343	0.00107	CcSEcCtD
Etravirine—Urinary tract disorder—Estradiol—osteoporosis	0.000343	0.00107	CcSEcCtD
Etravirine—Vomiting—Etidronic acid—osteoporosis	0.000343	0.00107	CcSEcCtD
Etravirine—Connective tissue disorder—Estradiol—osteoporosis	0.000341	0.00106	CcSEcCtD
Etravirine—Urethral disorder—Estradiol—osteoporosis	0.00034	0.00106	CcSEcCtD
Etravirine—Rash—Etidronic acid—osteoporosis	0.00034	0.00106	CcSEcCtD
Etravirine—Convulsion—Zoledronate—osteoporosis	0.00034	0.00106	CcSEcCtD
Etravirine—Dermatitis—Etidronic acid—osteoporosis	0.00034	0.00106	CcSEcCtD
Etravirine—Vertigo—Conjugated Estrogens—osteoporosis	0.000339	0.00106	CcSEcCtD
Etravirine—Hyperhidrosis—Pamidronate—osteoporosis	0.000339	0.00106	CcSEcCtD
Etravirine—Syncope—Conjugated Estrogens—osteoporosis	0.000339	0.00106	CcSEcCtD
Etravirine—Hypertension—Zoledronate—osteoporosis	0.000339	0.00106	CcSEcCtD
Etravirine—ABCB1—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.000339	0.0129	CbGpPWpGaD
Etravirine—Hypersensitivity—Alendronate—osteoporosis	0.000339	0.00106	CcSEcCtD
Etravirine—Headache—Etidronic acid—osteoporosis	0.000338	0.00105	CcSEcCtD
Etravirine—Asthenia—Estropipate—osteoporosis	0.000335	0.00104	CcSEcCtD
Etravirine—Anorexia—Pamidronate—osteoporosis	0.000334	0.00104	CcSEcCtD
Etravirine—Insomnia—Risedronate—osteoporosis	0.000334	0.00104	CcSEcCtD
Etravirine—Anxiety—Zoledronate—osteoporosis	0.000333	0.00104	CcSEcCtD
Etravirine—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000332	0.00103	CcSEcCtD
Etravirine—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000332	0.00103	CcSEcCtD
Etravirine—Paraesthesia—Risedronate—osteoporosis	0.000331	0.00103	CcSEcCtD
Etravirine—Discomfort—Zoledronate—osteoporosis	0.00033	0.00103	CcSEcCtD
Etravirine—Asthenia—Alendronate—osteoporosis	0.00033	0.00103	CcSEcCtD
Etravirine—Hypersensitivity—Ibandronate—osteoporosis	0.00033	0.00103	CcSEcCtD
Etravirine—Erythema multiforme—Estradiol—osteoporosis	0.000328	0.00102	CcSEcCtD
Etravirine—Convulsion—Conjugated Estrogens—osteoporosis	0.000327	0.00102	CcSEcCtD
Etravirine—Dry mouth—Zoledronate—osteoporosis	0.000327	0.00102	CcSEcCtD
Etravirine—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000327	0.00102	CcSEcCtD
Etravirine—Fatigue—Ethinyl Estradiol—osteoporosis	0.000326	0.00102	CcSEcCtD
Etravirine—Eye disorder—Estradiol—osteoporosis	0.000325	0.00101	CcSEcCtD
Etravirine—Constipation—Ethinyl Estradiol—osteoporosis	0.000323	0.00101	CcSEcCtD
Etravirine—Confusional state—Zoledronate—osteoporosis	0.000323	0.00101	CcSEcCtD
Etravirine—Hypersensitivity—Calcitriol—osteoporosis	0.000323	0.00101	CcSEcCtD
Etravirine—Cardiac disorder—Estradiol—osteoporosis	0.000322	0.001	CcSEcCtD
Etravirine—Asthenia—Ibandronate—osteoporosis	0.000321	0.001	CcSEcCtD
Etravirine—Anxiety—Conjugated Estrogens—osteoporosis	0.000321	0.000999	CcSEcCtD
Etravirine—Nausea—Etidronic acid—osteoporosis	0.00032	0.000998	CcSEcCtD
Etravirine—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000319	0.000995	CcSEcCtD
Etravirine—Diarrhoea—Estropipate—osteoporosis	0.000319	0.000995	CcSEcCtD
Etravirine—Gastrointestinal disorder—Risedronate—osteoporosis	0.000318	0.000992	CcSEcCtD
Etravirine—Infection—Zoledronate—osteoporosis	0.000318	0.000991	CcSEcCtD
Etravirine—Fatigue—Risedronate—osteoporosis	0.000318	0.000991	CcSEcCtD
Etravirine—Insomnia—Pamidronate—osteoporosis	0.000317	0.000988	CcSEcCtD
Etravirine—Pain—Risedronate—osteoporosis	0.000315	0.000983	CcSEcCtD
Etravirine—Constipation—Risedronate—osteoporosis	0.000315	0.000983	CcSEcCtD
Etravirine—Angiopathy—Estradiol—osteoporosis	0.000315	0.000982	CcSEcCtD
Etravirine—Shock—Zoledronate—osteoporosis	0.000315	0.000982	CcSEcCtD
Etravirine—Paraesthesia—Pamidronate—osteoporosis	0.000315	0.000981	CcSEcCtD
Etravirine—Diarrhoea—Alendronate—osteoporosis	0.000314	0.00098	CcSEcCtD
Etravirine—Asthenia—Calcitriol—osteoporosis	0.000314	0.000979	CcSEcCtD
Etravirine—Nervous system disorder—Zoledronate—osteoporosis	0.000314	0.000979	CcSEcCtD
Etravirine—Immune system disorder—Estradiol—osteoporosis	0.000314	0.000978	CcSEcCtD
Etravirine—Thrombocytopenia—Zoledronate—osteoporosis	0.000314	0.000977	CcSEcCtD
Etravirine—Mediastinal disorder—Estradiol—osteoporosis	0.000313	0.000975	CcSEcCtD
Etravirine—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000312	0.000971	CcSEcCtD
Etravirine—Somnolence—Pamidronate—osteoporosis	0.000312	0.000971	CcSEcCtD
Etravirine—Skin disorder—Zoledronate—osteoporosis	0.000311	0.000969	CcSEcCtD
Etravirine—Hyperhidrosis—Zoledronate—osteoporosis	0.00031	0.000965	CcSEcCtD
Etravirine—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000309	0.000964	CcSEcCtD
Etravirine—Diarrhoea—Raloxifene—osteoporosis	0.000309	0.000964	CcSEcCtD
Etravirine—Dizziness—Estropipate—osteoporosis	0.000309	0.000962	CcSEcCtD
Etravirine—Infection—Conjugated Estrogens—osteoporosis	0.000306	0.000955	CcSEcCtD
Etravirine—Diarrhoea—Ibandronate—osteoporosis	0.000306	0.000954	CcSEcCtD
Etravirine—Anorexia—Zoledronate—osteoporosis	0.000305	0.000951	CcSEcCtD
Etravirine—Decreased appetite—Pamidronate—osteoporosis	0.000305	0.00095	CcSEcCtD
Etravirine—Mental disorder—Estradiol—osteoporosis	0.000304	0.000948	CcSEcCtD
Etravirine—Dizziness—Alendronate—osteoporosis	0.000304	0.000947	CcSEcCtD
Etravirine—Shock—Conjugated Estrogens—osteoporosis	0.000303	0.000945	CcSEcCtD
Etravirine—ABCB1—Allograft Rejection—TUBA1B—osteoporosis	0.000303	0.0116	CbGpPWpGaD
Etravirine—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000303	0.000943	CcSEcCtD
Etravirine—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000302	0.000942	CcSEcCtD
Etravirine—Malnutrition—Estradiol—osteoporosis	0.000302	0.000942	CcSEcCtD
Etravirine—Fatigue—Pamidronate—osteoporosis	0.000302	0.000942	CcSEcCtD
Etravirine—Gastrointestinal pain—Risedronate—osteoporosis	0.000302	0.00094	CcSEcCtD
Etravirine—Pain—Pamidronate—osteoporosis	0.0003	0.000934	CcSEcCtD
Etravirine—Constipation—Pamidronate—osteoporosis	0.0003	0.000934	CcSEcCtD
Etravirine—Diarrhoea—Calcitriol—osteoporosis	0.0003	0.000934	CcSEcCtD
Etravirine—Skin disorder—Conjugated Estrogens—osteoporosis	0.000299	0.000933	CcSEcCtD
Etravirine—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000299	0.000932	CcSEcCtD
Etravirine—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000299	0.000932	CcSEcCtD
Etravirine—Dizziness—Raloxifene—osteoporosis	0.000299	0.000931	CcSEcCtD
Etravirine—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000298	0.000929	CcSEcCtD
Etravirine—Flatulence—Estradiol—osteoporosis	0.000298	0.000928	CcSEcCtD
Etravirine—Tension—Estradiol—osteoporosis	0.000297	0.000925	CcSEcCtD
Etravirine—Vomiting—Estropipate—osteoporosis	0.000297	0.000925	CcSEcCtD
Etravirine—Dizziness—Ibandronate—osteoporosis	0.000296	0.000922	CcSEcCtD
Etravirine—Rash—Estropipate—osteoporosis	0.000294	0.000917	CcSEcCtD
Etravirine—Dermatitis—Estropipate—osteoporosis	0.000294	0.000916	CcSEcCtD
Etravirine—Anorexia—Conjugated Estrogens—osteoporosis	0.000294	0.000916	CcSEcCtD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.000294	0.0112	CbGpPWpGaD
Etravirine—Nervousness—Estradiol—osteoporosis	0.000294	0.000915	CcSEcCtD
Etravirine—Headache—Estropipate—osteoporosis	0.000292	0.000911	CcSEcCtD
Etravirine—Vomiting—Alendronate—osteoporosis	0.000292	0.000911	CcSEcCtD
Etravirine—Body temperature increased—Risedronate—osteoporosis	0.000292	0.000908	CcSEcCtD
Etravirine—Abdominal pain—Risedronate—osteoporosis	0.000292	0.000908	CcSEcCtD
Etravirine—Rash—Alendronate—osteoporosis	0.00029	0.000903	CcSEcCtD
Etravirine—Insomnia—Zoledronate—osteoporosis	0.00029	0.000903	CcSEcCtD
Etravirine—Dermatitis—Alendronate—osteoporosis	0.00029	0.000902	CcSEcCtD
Etravirine—Feeling abnormal—Pamidronate—osteoporosis	0.000289	0.0009	CcSEcCtD
Etravirine—Headache—Alendronate—osteoporosis	0.000288	0.000897	CcSEcCtD
Etravirine—Paraesthesia—Zoledronate—osteoporosis	0.000288	0.000896	CcSEcCtD
Etravirine—Vomiting—Raloxifene—osteoporosis	0.000287	0.000896	CcSEcCtD
Etravirine—Gastrointestinal pain—Pamidronate—osteoporosis	0.000287	0.000893	CcSEcCtD
Etravirine—Rash—Raloxifene—osteoporosis	0.000285	0.000888	CcSEcCtD
Etravirine—Dermatitis—Raloxifene—osteoporosis	0.000285	0.000887	CcSEcCtD
Etravirine—Somnolence—Zoledronate—osteoporosis	0.000285	0.000887	CcSEcCtD
Etravirine—Vomiting—Ibandronate—osteoporosis	0.000284	0.000887	CcSEcCtD
Etravirine—Tremor—Estradiol—osteoporosis	0.000283	0.000883	CcSEcCtD
Etravirine—Headache—Raloxifene—osteoporosis	0.000283	0.000882	CcSEcCtD
Etravirine—Rash—Ibandronate—osteoporosis	0.000282	0.000879	CcSEcCtD
Etravirine—Dermatitis—Ibandronate—osteoporosis	0.000282	0.000878	CcSEcCtD
Etravirine—Ill-defined disorder—Estradiol—osteoporosis	0.000281	0.000874	CcSEcCtD
Etravirine—Headache—Ibandronate—osteoporosis	0.00028	0.000874	CcSEcCtD
Etravirine—Insomnia—Conjugated Estrogens—osteoporosis	0.000279	0.000869	CcSEcCtD
Etravirine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000279	0.000868	CcSEcCtD
Etravirine—Vomiting—Calcitriol—osteoporosis	0.000278	0.000868	CcSEcCtD
Etravirine—Decreased appetite—Zoledronate—osteoporosis	0.000278	0.000867	CcSEcCtD
Etravirine—Nausea—Estropipate—osteoporosis	0.000277	0.000864	CcSEcCtD
Etravirine—Abdominal pain—Pamidronate—osteoporosis	0.000277	0.000864	CcSEcCtD
Etravirine—Body temperature increased—Pamidronate—osteoporosis	0.000277	0.000864	CcSEcCtD
Etravirine—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000277	0.000863	CcSEcCtD
Etravirine—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000276	0.000861	CcSEcCtD
Etravirine—Angioedema—Estradiol—osteoporosis	0.000276	0.000861	CcSEcCtD
Etravirine—Rash—Calcitriol—osteoporosis	0.000276	0.000861	CcSEcCtD
Etravirine—Fatigue—Zoledronate—osteoporosis	0.000276	0.00086	CcSEcCtD
Etravirine—Dermatitis—Calcitriol—osteoporosis	0.000276	0.00086	CcSEcCtD
Etravirine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000276	0.0105	CbGpPWpGaD
Etravirine—Headache—Calcitriol—osteoporosis	0.000274	0.000855	CcSEcCtD
Etravirine—Somnolence—Conjugated Estrogens—osteoporosis	0.000274	0.000854	CcSEcCtD
Etravirine—Pain—Zoledronate—osteoporosis	0.000274	0.000853	CcSEcCtD
Etravirine—Constipation—Zoledronate—osteoporosis	0.000274	0.000853	CcSEcCtD
Etravirine—Nausea—Alendronate—osteoporosis	0.000273	0.000851	CcSEcCtD
Etravirine—Malaise—Estradiol—osteoporosis	0.000273	0.00085	CcSEcCtD
Etravirine—CYP2C19—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000272	0.0104	CbGpPWpGaD
Etravirine—Hypersensitivity—Risedronate—osteoporosis	0.000272	0.000847	CcSEcCtD
Etravirine—Vertigo—Estradiol—osteoporosis	0.000272	0.000847	CcSEcCtD
Etravirine—Asthenia—Ethinyl Estradiol—osteoporosis	0.000271	0.000846	CcSEcCtD
Etravirine—Syncope—Estradiol—osteoporosis	0.000271	0.000845	CcSEcCtD
Etravirine—Nausea—Raloxifene—osteoporosis	0.000268	0.000837	CcSEcCtD
Etravirine—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000268	0.000835	CcSEcCtD
Etravirine—ABCB4—Metabolism—PKM—osteoporosis	0.000268	0.0102	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—FDPS—osteoporosis	0.000268	0.0102	CbGpPWpGaD
Etravirine—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000266	0.00083	CcSEcCtD
Etravirine—Fatigue—Conjugated Estrogens—osteoporosis	0.000266	0.000828	CcSEcCtD
Etravirine—Nausea—Ibandronate—osteoporosis	0.000266	0.000828	CcSEcCtD
Etravirine—Loss of consciousness—Estradiol—osteoporosis	0.000266	0.000828	CcSEcCtD
Etravirine—Asthenia—Risedronate—osteoporosis	0.000265	0.000824	CcSEcCtD
Etravirine—Feeling abnormal—Zoledronate—osteoporosis	0.000264	0.000822	CcSEcCtD
Etravirine—Constipation—Conjugated Estrogens—osteoporosis	0.000264	0.000822	CcSEcCtD
Etravirine—Pain—Conjugated Estrogens—osteoporosis	0.000264	0.000822	CcSEcCtD
Etravirine—Gastrointestinal pain—Zoledronate—osteoporosis	0.000262	0.000816	CcSEcCtD
Etravirine—Hypertension—Estradiol—osteoporosis	0.000261	0.000813	CcSEcCtD
Etravirine—Nausea—Calcitriol—osteoporosis	0.00026	0.000811	CcSEcCtD
Etravirine—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000259	0.000806	CcSEcCtD
Etravirine—Hypersensitivity—Pamidronate—osteoporosis	0.000258	0.000805	CcSEcCtD
Etravirine—Anxiety—Estradiol—osteoporosis	0.000257	0.000799	CcSEcCtD
Etravirine—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000256	0.000797	CcSEcCtD
Etravirine—Discomfort—Estradiol—osteoporosis	0.000254	0.000793	CcSEcCtD
Etravirine—ABCB4—Metabolism—PGLS—osteoporosis	0.000254	0.00969	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—GPD2—osteoporosis	0.000254	0.00969	CbGpPWpGaD
Etravirine—Abdominal pain—Zoledronate—osteoporosis	0.000253	0.000789	CcSEcCtD
Etravirine—Body temperature increased—Zoledronate—osteoporosis	0.000253	0.000789	CcSEcCtD
Etravirine—Diarrhoea—Risedronate—osteoporosis	0.000252	0.000786	CcSEcCtD
Etravirine—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000252	0.000786	CcSEcCtD
Etravirine—Dry mouth—Estradiol—osteoporosis	0.000252	0.000785	CcSEcCtD
Etravirine—Asthenia—Pamidronate—osteoporosis	0.000252	0.000784	CcSEcCtD
Etravirine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000251	0.00958	CbGpPWpGaD
Etravirine—Dizziness—Ethinyl Estradiol—osteoporosis	0.00025	0.000779	CcSEcCtD
Etravirine—Confusional state—Estradiol—osteoporosis	0.000249	0.000775	CcSEcCtD
Etravirine—CYP2C9—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000248	0.00946	CbGpPWpGaD
Etravirine—Infection—Estradiol—osteoporosis	0.000245	0.000764	CcSEcCtD
Etravirine—Dizziness—Risedronate—osteoporosis	0.000244	0.00076	CcSEcCtD
Etravirine—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000244	0.00076	CcSEcCtD
Etravirine—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000244	0.00076	CcSEcCtD
Etravirine—Shock—Estradiol—osteoporosis	0.000243	0.000757	CcSEcCtD
Etravirine—Nervous system disorder—Estradiol—osteoporosis	0.000242	0.000754	CcSEcCtD
Etravirine—Vomiting—Ethinyl Estradiol—osteoporosis	0.00024	0.000749	CcSEcCtD
Etravirine—Diarrhoea—Pamidronate—osteoporosis	0.00024	0.000747	CcSEcCtD
Etravirine—Skin disorder—Estradiol—osteoporosis	0.00024	0.000747	CcSEcCtD
Etravirine—Hyperhidrosis—Estradiol—osteoporosis	0.000239	0.000743	CcSEcCtD
Etravirine—Rash—Ethinyl Estradiol—osteoporosis	0.000238	0.000743	CcSEcCtD
Etravirine—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000238	0.000742	CcSEcCtD
Etravirine—Headache—Ethinyl Estradiol—osteoporosis	0.000237	0.000738	CcSEcCtD
Etravirine—Hypersensitivity—Zoledronate—osteoporosis	0.000236	0.000735	CcSEcCtD
Etravirine—Vomiting—Risedronate—osteoporosis	0.000234	0.000731	CcSEcCtD
Etravirine—Rash—Risedronate—osteoporosis	0.000233	0.000725	CcSEcCtD
Etravirine—ABCB4—Metabolism—PNP—osteoporosis	0.000232	0.00886	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—ATIC—osteoporosis	0.000232	0.00886	CbGpPWpGaD
Etravirine—Dermatitis—Risedronate—osteoporosis	0.000232	0.000724	CcSEcCtD
Etravirine—Dizziness—Pamidronate—osteoporosis	0.000232	0.000722	CcSEcCtD
Etravirine—Headache—Risedronate—osteoporosis	0.000231	0.00072	CcSEcCtD
Etravirine—Asthenia—Zoledronate—osteoporosis	0.00023	0.000716	CcSEcCtD
Etravirine—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000227	0.000708	CcSEcCtD
Etravirine—Nausea—Ethinyl Estradiol—osteoporosis	0.000225	0.0007	CcSEcCtD
Etravirine—CYP2C19—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000223	0.00852	CbGpPWpGaD
Etravirine—Insomnia—Estradiol—osteoporosis	0.000223	0.000696	CcSEcCtD
Etravirine—Vomiting—Pamidronate—osteoporosis	0.000223	0.000695	CcSEcCtD
Etravirine—Paraesthesia—Estradiol—osteoporosis	0.000222	0.00069	CcSEcCtD
Etravirine—Asthenia—Conjugated Estrogens—osteoporosis	0.000221	0.000689	CcSEcCtD
Etravirine—Rash—Pamidronate—osteoporosis	0.000221	0.000689	CcSEcCtD
Etravirine—Dermatitis—Pamidronate—osteoporosis	0.000221	0.000688	CcSEcCtD
Etravirine—Headache—Pamidronate—osteoporosis	0.00022	0.000684	CcSEcCtD
Etravirine—Somnolence—Estradiol—osteoporosis	0.000219	0.000684	CcSEcCtD
Etravirine—Diarrhoea—Zoledronate—osteoporosis	0.000219	0.000683	CcSEcCtD
Etravirine—Nausea—Risedronate—osteoporosis	0.000219	0.000683	CcSEcCtD
Etravirine—Decreased appetite—Estradiol—osteoporosis	0.000215	0.000668	CcSEcCtD
Etravirine—Gastrointestinal disorder—Estradiol—osteoporosis	0.000213	0.000664	CcSEcCtD
Etravirine—Fatigue—Estradiol—osteoporosis	0.000213	0.000663	CcSEcCtD
Etravirine—Dizziness—Zoledronate—osteoporosis	0.000212	0.00066	CcSEcCtD
Etravirine—Constipation—Estradiol—osteoporosis	0.000211	0.000658	CcSEcCtD
Etravirine—Pain—Estradiol—osteoporosis	0.000211	0.000658	CcSEcCtD
Etravirine—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000211	0.000657	CcSEcCtD
Etravirine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.000209	0.00796	CbGpPWpGaD
Etravirine—Nausea—Pamidronate—osteoporosis	0.000208	0.000649	CcSEcCtD
Etravirine—Dizziness—Conjugated Estrogens—osteoporosis	0.000204	0.000635	CcSEcCtD
Etravirine—CYP2C9—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000204	0.00777	CbGpPWpGaD
Etravirine—Vomiting—Zoledronate—osteoporosis	0.000204	0.000634	CcSEcCtD
Etravirine—Feeling abnormal—Estradiol—osteoporosis	0.000203	0.000634	CcSEcCtD
Etravirine—Rash—Zoledronate—osteoporosis	0.000202	0.000629	CcSEcCtD
Etravirine—Gastrointestinal pain—Estradiol—osteoporosis	0.000202	0.000629	CcSEcCtD
Etravirine—Dermatitis—Zoledronate—osteoporosis	0.000202	0.000629	CcSEcCtD
Etravirine—Headache—Zoledronate—osteoporosis	0.000201	0.000625	CcSEcCtD
Etravirine—ABCB4—Metabolism—CA2—osteoporosis	0.000198	0.00754	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—OXCT1—osteoporosis	0.000198	0.00754	CbGpPWpGaD
Etravirine—Vomiting—Conjugated Estrogens—osteoporosis	0.000196	0.000611	CcSEcCtD
Etravirine—Body temperature increased—Estradiol—osteoporosis	0.000195	0.000608	CcSEcCtD
Etravirine—Abdominal pain—Estradiol—osteoporosis	0.000195	0.000608	CcSEcCtD
Etravirine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000195	0.00742	CbGpPWpGaD
Etravirine—Rash—Conjugated Estrogens—osteoporosis	0.000194	0.000606	CcSEcCtD
Etravirine—Dermatitis—Conjugated Estrogens—osteoporosis	0.000194	0.000605	CcSEcCtD
Etravirine—Headache—Conjugated Estrogens—osteoporosis	0.000193	0.000602	CcSEcCtD
Etravirine—ABCB4—Metabolism—MGLL—osteoporosis	0.000193	0.00734	CbGpPWpGaD
Etravirine—Nausea—Zoledronate—osteoporosis	0.00019	0.000593	CcSEcCtD
Etravirine—Nausea—Conjugated Estrogens—osteoporosis	0.000183	0.000571	CcSEcCtD
Etravirine—Hypersensitivity—Estradiol—osteoporosis	0.000182	0.000567	CcSEcCtD
Etravirine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000182	0.00693	CbGpPWpGaD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	0.000182	0.00693	CbGpPWpGaD
Etravirine—Asthenia—Estradiol—osteoporosis	0.000177	0.000552	CcSEcCtD
Etravirine—Diarrhoea—Estradiol—osteoporosis	0.000169	0.000526	CcSEcCtD
Etravirine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000166	0.00632	CbGpPWpGaD
Etravirine—ABCB1—HIF-1-alpha transcription factor network—ENO1—osteoporosis	0.000164	0.00625	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—IDH2—osteoporosis	0.000164	0.00624	CbGpPWpGaD
Etravirine—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000164	0.00624	CbGpPWpGaD
Etravirine—Dizziness—Estradiol—osteoporosis	0.000163	0.000509	CcSEcCtD
Etravirine—Vomiting—Estradiol—osteoporosis	0.000157	0.000489	CcSEcCtD
Etravirine—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	0.000156	0.00596	CbGpPWpGaD
Etravirine—Rash—Estradiol—osteoporosis	0.000156	0.000485	CcSEcCtD
Etravirine—Dermatitis—Estradiol—osteoporosis	0.000155	0.000484	CcSEcCtD
Etravirine—Headache—Estradiol—osteoporosis	0.000155	0.000482	CcSEcCtD
Etravirine—ABCB4—Metabolism—CYP27A1—osteoporosis	0.000154	0.00587	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—ACP5—osteoporosis	0.00015	0.00571	CbGpPWpGaD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	0.000148	0.00564	CbGpPWpGaD
Etravirine—Nausea—Estradiol—osteoporosis	0.000147	0.000457	CcSEcCtD
Etravirine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000145	0.00552	CbGpPWpGaD
Etravirine—CYP2C19—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000143	0.00545	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—TPI1—osteoporosis	0.000139	0.00531	CbGpPWpGaD
Etravirine—CYP2C19—Arachidonic acid metabolism—GPX1—osteoporosis	0.000136	0.0052	CbGpPWpGaD
Etravirine—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000134	0.00512	CbGpPWpGaD
Etravirine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000132	0.00503	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—P4HB—osteoporosis	0.000131	0.00499	CbGpPWpGaD
Etravirine—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.00013	0.00497	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—GAPDH—osteoporosis	0.000128	0.0049	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—RAP1A—osteoporosis	0.000125	0.00477	CbGpPWpGaD
Etravirine—CYP2C9—Arachidonic acid metabolism—GPX1—osteoporosis	0.000124	0.00474	CbGpPWpGaD
Etravirine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.00012	0.00457	CbGpPWpGaD
Etravirine—CYP2C19—Biological oxidations—CYP27A1—osteoporosis	0.000119	0.00453	CbGpPWpGaD
Etravirine—CYP2C19—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000117	0.00448	CbGpPWpGaD
Etravirine—CYP2C19—Metapathway biotransformation—CYP27A1—osteoporosis	0.000117	0.00446	CbGpPWpGaD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—POMC—osteoporosis	0.000109	0.00416	CbGpPWpGaD
Etravirine—CYP2C9—Biological oxidations—CYP27A1—osteoporosis	0.000108	0.00413	CbGpPWpGaD
Etravirine—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	0.000108	0.00411	CbGpPWpGaD
Etravirine—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000107	0.00408	CbGpPWpGaD
Etravirine—CYP2C9—Metapathway biotransformation—CYP27A1—osteoporosis	0.000107	0.00407	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—ENO1—osteoporosis	0.000101	0.00386	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—PSMA2—osteoporosis	9.97e-05	0.0038	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—PSMA5—osteoporosis	9.97e-05	0.0038	CbGpPWpGaD
Etravirine—ABCB1—HIF-1-alpha transcription factor network—LEP—osteoporosis	9.16e-05	0.00349	CbGpPWpGaD
Etravirine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	8.7e-05	0.00332	CbGpPWpGaD
Etravirine—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	8.7e-05	0.00332	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	8.66e-05	0.0033	CbGpPWpGaD
Etravirine—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	8.59e-05	0.00328	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—CYP19A1—osteoporosis	8.09e-05	0.00308	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	7.93e-05	0.00303	CbGpPWpGaD
Etravirine—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	7.93e-05	0.00303	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	7.52e-05	0.00287	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	7.23e-05	0.00276	CbGpPWpGaD
Etravirine—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	7.14e-05	0.00272	CbGpPWpGaD
Etravirine—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	7.06e-05	0.00269	CbGpPWpGaD
Etravirine—CYP2C19—Phase 1 - Functionalization of compounds—POMC—osteoporosis	7.05e-05	0.00269	CbGpPWpGaD
Etravirine—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	7.04e-05	0.00268	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	6.86e-05	0.00262	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—ADCY5—osteoporosis	6.61e-05	0.00252	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—GPX1—osteoporosis	6.58e-05	0.00251	CbGpPWpGaD
Etravirine—CYP2C9—Phase 1 - Functionalization of compounds—POMC—osteoporosis	6.43e-05	0.00245	CbGpPWpGaD
Etravirine—CYP2C19—Biological oxidations—CYP19A1—osteoporosis	6.23e-05	0.00238	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	6.16e-05	0.00235	CbGpPWpGaD
Etravirine—CYP2C19—Metapathway biotransformation—CYP19A1—osteoporosis	6.15e-05	0.00234	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—MTHFR—osteoporosis	6.08e-05	0.00232	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	5.85e-05	0.00223	CbGpPWpGaD
Etravirine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—osteoporosis	5.77e-05	0.0022	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	5.7e-05	0.00217	CbGpPWpGaD
Etravirine—CYP2C9—Biological oxidations—CYP19A1—osteoporosis	5.68e-05	0.00217	CbGpPWpGaD
Etravirine—CYP2C9—Metapathway biotransformation—CYP19A1—osteoporosis	5.61e-05	0.00214	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	5.33e-05	0.00203	CbGpPWpGaD
Etravirine—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	5.23e-05	0.002	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	5.2e-05	0.00198	CbGpPWpGaD
Etravirine—ABCB1—Allograft Rejection—IL1B—osteoporosis	5.06e-05	0.00193	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—POMC—osteoporosis	4.86e-05	0.00185	CbGpPWpGaD
Etravirine—ABCB1—Transmembrane transport of small molecules—ANXA2—osteoporosis	4.84e-05	0.00185	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	4.56e-05	0.00174	CbGpPWpGaD
Etravirine—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	4.24e-05	0.00162	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	4.15e-05	0.00158	CbGpPWpGaD
Etravirine—ABCB1—Allograft Rejection—TGFB1—osteoporosis	3.93e-05	0.0015	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	3.87e-05	0.00148	CbGpPWpGaD
Etravirine—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	3.75e-05	0.00143	CbGpPWpGaD
Etravirine—CYP2C19—Biological oxidations—POMC—osteoporosis	3.75e-05	0.00143	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	3.74e-05	0.00143	CbGpPWpGaD
Etravirine—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	3.7e-05	0.00141	CbGpPWpGaD
Etravirine—ABCB1—Allograft Rejection—TNF—osteoporosis	3.67e-05	0.0014	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—FDPS—osteoporosis	3.53e-05	0.00135	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PKM—osteoporosis	3.53e-05	0.00135	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	3.53e-05	0.00135	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—FDPS—osteoporosis	3.45e-05	0.00132	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PKM—osteoporosis	3.45e-05	0.00132	CbGpPWpGaD
Etravirine—CYP2C9—Biological oxidations—POMC—osteoporosis	3.42e-05	0.0013	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PGLS—osteoporosis	3.35e-05	0.00128	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—GPD2—osteoporosis	3.35e-05	0.00128	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—GPD2—osteoporosis	3.27e-05	0.00125	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PGLS—osteoporosis	3.27e-05	0.00125	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	3.23e-05	0.00123	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PKM—osteoporosis	3.22e-05	0.00123	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—FDPS—osteoporosis	3.22e-05	0.00123	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—ATIC—osteoporosis	3.06e-05	0.00117	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PNP—osteoporosis	3.06e-05	0.00117	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PGLS—osteoporosis	3.05e-05	0.00116	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—GPD2—osteoporosis	3.05e-05	0.00116	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PNP—osteoporosis	2.99e-05	0.00114	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—ATIC—osteoporosis	2.99e-05	0.00114	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PNP—osteoporosis	2.79e-05	0.00107	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—ATIC—osteoporosis	2.79e-05	0.00107	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—CA2—osteoporosis	2.6e-05	0.000993	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—OXCT1—osteoporosis	2.6e-05	0.000993	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—OXCT1—osteoporosis	2.54e-05	0.00097	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—CA2—osteoporosis	2.54e-05	0.00097	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—MGLL—osteoporosis	2.54e-05	0.000968	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—MGLL—osteoporosis	2.48e-05	0.000945	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.39e-05	0.000913	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—CA2—osteoporosis	2.37e-05	0.000906	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—OXCT1—osteoporosis	2.37e-05	0.000906	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—MGLL—osteoporosis	2.31e-05	0.000883	CbGpPWpGaD
Etravirine—CYP3A4—Biological oxidations—POMC—osteoporosis	2.25e-05	0.000859	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.18e-05	0.000832	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—IDH2—osteoporosis	2.16e-05	0.000823	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PKM—osteoporosis	2.12e-05	0.00081	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—FDPS—osteoporosis	2.12e-05	0.00081	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—IDH2—osteoporosis	2.11e-05	0.000803	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—CYP27A1—osteoporosis	2.03e-05	0.000774	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PGLS—osteoporosis	2.01e-05	0.000768	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—GPD2—osteoporosis	2.01e-05	0.000768	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—CYP27A1—osteoporosis	1.98e-05	0.000755	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—ACP5—osteoporosis	1.97e-05	0.000753	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—IDH2—osteoporosis	1.97e-05	0.000751	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.95e-05	0.000743	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	1.94e-05	0.000741	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	1.94e-05	0.00074	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—ACP5—osteoporosis	1.93e-05	0.000735	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—CYP27A1—osteoporosis	1.85e-05	0.000706	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PNP—osteoporosis	1.84e-05	0.000703	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—ATIC—osteoporosis	1.84e-05	0.000703	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—TPI1—osteoporosis	1.84e-05	0.0007	CbGpPWpGaD
Etravirine—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.81e-05	0.000692	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	1.81e-05	0.000691	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—ACP5—osteoporosis	1.8e-05	0.000687	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—TPI1—osteoporosis	1.79e-05	0.000683	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.78e-05	0.000678	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—P4HB—osteoporosis	1.73e-05	0.000658	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—GAPDH—osteoporosis	1.69e-05	0.000646	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—P4HB—osteoporosis	1.68e-05	0.000642	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—TPI1—osteoporosis	1.67e-05	0.000638	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—GAPDH—osteoporosis	1.65e-05	0.00063	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—RAP1A—osteoporosis	1.65e-05	0.000629	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—RAP1A—osteoporosis	1.61e-05	0.000614	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—P4HB—osteoporosis	1.57e-05	0.0006	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—CA2—osteoporosis	1.57e-05	0.000597	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—OXCT1—osteoporosis	1.57e-05	0.000597	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—GAPDH—osteoporosis	1.54e-05	0.000589	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—MGLL—osteoporosis	1.53e-05	0.000582	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—RAP1A—osteoporosis	1.5e-05	0.000574	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.44e-05	0.000549	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—ENO1—osteoporosis	1.33e-05	0.000509	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PSMA2—osteoporosis	1.31e-05	0.000501	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PSMA5—osteoporosis	1.31e-05	0.000501	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.31e-05	0.0005	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—ENO1—osteoporosis	1.3e-05	0.000496	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—IDH2—osteoporosis	1.3e-05	0.000495	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PSMA2—osteoporosis	1.28e-05	0.000489	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PSMA5—osteoporosis	1.28e-05	0.000489	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—CYP27A1—osteoporosis	1.22e-05	0.000465	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—ENO1—osteoporosis	1.22e-05	0.000464	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PSMA2—osteoporosis	1.2e-05	0.000457	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PSMA5—osteoporosis	1.2e-05	0.000457	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—ACP5—osteoporosis	1.19e-05	0.000453	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—TPI1—osteoporosis	1.1e-05	0.000421	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—CYP19A1—osteoporosis	1.07e-05	0.000407	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—CYP19A1—osteoporosis	1.04e-05	0.000397	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—P4HB—osteoporosis	1.04e-05	0.000396	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—GAPDH—osteoporosis	1.02e-05	0.000388	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—RAP1A—osteoporosis	9.92e-06	0.000378	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—CYP19A1—osteoporosis	9.72e-06	0.000371	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—ADCY5—osteoporosis	8.71e-06	0.000332	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—GPX1—osteoporosis	8.68e-06	0.000331	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—ADCY5—osteoporosis	8.5e-06	0.000324	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—GPX1—osteoporosis	8.47e-06	0.000323	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—ENO1—osteoporosis	8.02e-06	0.000306	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—MTHFR—osteoporosis	8.01e-06	0.000306	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—ADCY5—osteoporosis	7.94e-06	0.000303	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—GPX1—osteoporosis	7.91e-06	0.000302	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PSMA2—osteoporosis	7.9e-06	0.000301	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PSMA5—osteoporosis	7.9e-06	0.000301	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—MTHFR—osteoporosis	7.82e-06	0.000298	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—MTHFR—osteoporosis	7.3e-06	0.000279	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—CYP19A1—osteoporosis	6.41e-06	0.000244	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—POMC—osteoporosis	6.41e-06	0.000244	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—POMC—osteoporosis	6.25e-06	0.000238	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—POMC—osteoporosis	5.84e-06	0.000223	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—ADCY5—osteoporosis	5.24e-06	0.0002	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—GPX1—osteoporosis	5.22e-06	0.000199	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—MTHFR—osteoporosis	4.82e-06	0.000184	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—POMC—osteoporosis	3.85e-06	0.000147	CbGpPWpGaD
